Ginkgo Bioworks Holdings (DNA) Other Non Operating Income (2021 - 2026)
Ginkgo Bioworks Holdings (DNA) reported Other Non Operating Income of -$4.8 million for Q1 2026, down 111.78% on a YoY basis from $40.5 million in Q1 2025, and up 55.22% quarter-over-quarter from -$10.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Other Non Operating Income for 6 years, with the latest figure at -$4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 111.78% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$1.2 million (up 44.14% YoY), and the FY2025 full-year result was $1.7 million, down 86.3% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$4.8 million, up from -$10.6 million in the prior quarter.
- The five-year high for Other Non Operating Income was $82.6 million in Q1 2022, with the low at -$33.8 million in Q4 2023.
- Historically, Other Non Operating Income has averaged $4.0 million across 5 years, with a median of -$1.6 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non Operating Income sank 552.2% — and 2025, when it soared 688.5%.
- Ginkgo Bioworks Holdings' Other Non Operating Income stood at $43.0 million in 2022, then plunged by 178.52% to -$33.8 million in 2023, then jumped by 87.41% to -$4.3 million in 2024, then sank by 150.22% to -$10.6 million in 2025, then jumped by 55.22% to -$4.8 million in 2026.
- The last three Other Non Operating Income figures came in at -$4.8 million (Q1 2026), -$10.6 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 546.79 Mn | 546.79 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.77 Mn |
| Dec 31, 2025 | -10.64 Mn |
| Sep 30, 2025 | 9.26 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | -2.25 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Sep 30, 2024 | -1.57 Mn |
| Jun 30, 2024 | 5.95 Mn |
| Mar 31, 2024 | 12.12 Mn |
| Dec 31, 2023 | -33.78 Mn |
| Sep 30, 2023 | -16.52 Mn |
| Jun 30, 2023 | 10.90 Mn |
| Mar 31, 2023 | 10.86 Mn |
| Dec 31, 2022 | 43.02 Mn |
| Sep 30, 2022 | -15.22 Mn |
| Jun 30, 2022 | -22.84 Mn |
| Mar 31, 2022 | 82.59 Mn |
| Dec 31, 2021 | 79.06 Mn |
| Sep 30, 2021 | -75.94 Mn |
| Jun 30, 2021 | 5.05 Mn |